Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.32 |
| ▸ | GLI1 | P08151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18991404 | 1.00 | GABRR1 (0.40) | GABRR1ALDH1A1TSHRGABRR2GRM2 | |
| SCHEMBL11826262 | 0.89 | ALDH1A1 (0.42) | ALDH1A1TSHRCTSBCTSSCTSK | |
| SCHEMBL11826258 | 0.89 | ALDH1A1 (0.42) | ALDH1A1TSHRCTSBCTSSCTSK | |
| SCHEMBL10208151 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHRCTSBCTSSCTSK | |
| SCHEMBL13863235 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHRCTSBCTSSCTSK | |
| SCHEMBL18992125 | 0.78 | EPHX1 (0.37) | ALDH1A1TSHRCTSBCTSSCTSK | |
| SCHEMBL7681466 | 0.78 | GABRR1 (0.34) | GABRR1ALDH1A1GABRR2GRM2 | |
| SCHEMBL5555921 | 0.78 | MCL1 (0.35) | GABRR1GABRR2GRM2 | |
| SCHEMBL18042386 | 0.78 | MCL1 (0.35) | GABRR1GABRR2GRM2 | |
| SCHEMBL6441767 | 0.78 | MCL1 (0.35) | GABRR1GABRR2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-7847041-B2 | Cobalt-catalyzed asymmetric cyclopropanation of electron-deficient olefins | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100076239-A1 | ASYMMETRIC CYCLOPROPANATION OF ELECTRON-DEFICIENT OLEFINS WITH DIAZO REAGENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090069519-A1 | COBALT-CATALYZED ASYMMETRIC CYCLOPROPANATION OF ELECTRON-DEFICIENT OLEFINS | NATIONAL SCIENCE FOUNDATION | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076239-A1 | ASYMMETRIC CYCLOPROPANATION OF ELECTRON-DEFICIENT OLEFINS WITH DIAZO REAGENTS | DUOX2, DUOX1, PPOX | GABRR1 2027/4885ALDH1A1 1047/4885TSHR 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.